LLY News and Press, Eli Lilly and Company

2024-05-02 19:23:00 ET By almost any measure, Eli Lilly (NYSE: LLY) stock has been a standout so far in 2024. Using a basic yardstick, the pharmaceutical sector giant's share price has climbed by over 33%, against the S&P 500 index's 5%. A mix of well-established commerciali...

2024-05-02 17:40:21 ET More on Amgen Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line ...

2024-05-02 15:10:06 ET More on Eli Lilly, Palatin Tech, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise GLP-1 drug pri...

2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...

2024-05-02 09:58:32 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise Novo Nordisk s...

2024-05-02 09:17:44 ET More on Novo Nordisk Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Novo Nordisk lifts guidance as Ozempic,...

2024-05-02 05:45:00 ET Shares of Eli Lilly and Company (NYSE: LLY) have soared nearly 35% so far in 2024 and are only a few points away from doubling over the last 12 months. The company reigns as the biggest drugmaker in the world based on market cap. It's also the largest company ...

2024-05-02 04:11:57 ET More on Novo Nordisk Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Novo Nordisk reports Q1 results; update...

2024-05-01 17:07:44 ET Summary Amgen Inc. shares have dropped some 20% since reaching an all-time high in February due to a below-consensus outlook and patent concerns. The company's four pillars of growth are General Medicine, Oncology, Inflammatory Diseases, and Rare Diseases. ...

2024-05-01 14:41:05 ET Summary Eli Lilly and Company's revenue for the first quarter of 2024 fell short of analysts' expectations, but the company exceeded forecasts on the bottom line. Sales of the company's obesity and diabetes drugs, particularly Mounjaro and Zepbound, saw sign...